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Abstract
Background: METARTHROS (Metabolic impact on joint and bone disease) is a nationwide German network to
investigate the overlap between inflammatory and metabolic diseases. The objective of this study was to compare
the body mass index (BMI) distribution in patients with early and established rheumatoid arthritis (RA) with data
from the general population, and to evaluate the association of BMI with patient characteristics and clinical markers.
Methods: The BMI distribution was examined with data collected at inclusion of patients in the early arthritis
cohort CAPEA, the biologics register RABBIT, and the National database of the German Collaborative Arthritis
Centers. A data source with a representative sample of the German population (German Ageing Survey) was used
as a comparator. BMI categories of <18.5 kg/m2 (underweight), 18.5 to <25 kg/m2 (normal weight), 25 to
<30 kg/m2 (overweight), and ≥30 kg/m2 (obese) were used. Patients were stratified by age and sex, and compared
to controls from the German Ageing Survey. Associations between BMI and markers of disease activity were
analysed with non-parametric tests and linear models.
Results: Data from 1207 (CAPEA), 12,230 (RABBIT), and 3424 (National database) RA patients and 6202 population
controls were evaluated. The mean age was 56, 56, 62, and 62 years, respectively, the mean disease duration was
13 weeks, 9.9 years, and 13.5 years, respectively, and the mean disease activity score (DAS28) was 5.1, 5.2, and 3.1,
respectively. In all RA cohorts, obesity was more frequent (23.8 %, 23.4 %, 21.4 %, respectively) than in controls (18.2 %).
This applied to all age groups <70 years, was independent of disease duration, and was more pronounced in females.
In all cohorts, the age at RA onset was associated with BMI, being higher in overweight/obese patients compared to
normal-weight patients. Current smoking was negatively associated with BMI. Linear analyses revealed increased
erythrocyte sedimentation rate (ESR) values in underweight and obese females, and an increasing disparity between
tender joint counts (TJCs) and swollen joint counts (SJCs) in higher BMI categories.
Conclusions: Compared to the general population, a higher prevalence of obesity was observed in all RA cohorts. The
dominance of obesity in females and the different behaviour of disease activity markers in relation to the BMI in
females indicate that additional parameters need to be considered when analysing the impact of obesity on
inflammation in RA.
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Background
Obesity has become a common condition in prosperous
countries and its global rise has lead to subsequent mor-
bidities. This situation also applies to auto-immune dis-
eases such as rheumatoid arthritis (RA). Adipose tissue
is known to have immunomodulatory as well as pro-
inflammatory properties. Obesity impacts the develop-
ment and progression of RA at different stages of the
disease [1, 2]. Positive associations between obesity and
the risk of developing RA have been reported, dominat-
ing in females [1, 3, 4]. The body composition is already
altered in patients with early RA with more fat and less
lean mass, with or without an increase in the body mass
index (BMI) [5]. Various studies describe the association
between high BMI categories and poorer clinical out-
comes, a lower chance for remission, and a higher prob-
ability of comorbidity but less radiographic joint damage
[2, 6]. Furthermore, sex-specific and conflicting results
have been reported concerning inflammatory markers
[6]. Additional factors, such as age, lifestyle, social status,
physical activity, or comorbid conditions, may also influ-
ence the association between body weight and inflam-
mation. Thus, some of these interactions may explain
divergent results on the association with inflammatory
markers in previous reports. Until now, the role of obes-
ity in the course of RA and its involved mechanisms
remain only incompletely understood [6].
METARTHROS (Metabolic impact on joint and bone
disease) is a nationwide collaborative German network
to investigate the interaction between inflammatory and
metabolic diseases. The focus of this study was to inves-
tigate the prevalence of underweight, overweight and
obese individuals in three large RA databases compared
to representative data from the general population. In
addition, the association of BMI status with socio-




Three RA databases were used for analysis. The ‘Course
And Prognosis of Early Arthritis’ (CAPEA) inception
cohort is a prospective multicentre, non-interventional,
observational study investigating the prognostic value of
early symptoms for the development of a chronic disease
course in patients with early arthritis. Patients with
symptom duration of less than 6 months were included
between 2010 and 2013 in 89 German rheumatologic in-
stitutions and were followed for 24 months [7]. Patients
were included consecutively. The data at inclusion were
selected. Only patients with a clinical RA diagnosis at
the last documented visit were included in the analysis.
The National Database (NDB) of the German Collab-
orative Arthritis Centres is an on-going prospective
study that was established in 1993 as a long-term moni-
toring system for German rheumatology patients. The
database contains annually updated clinical data and
patient-reported outcomes for unselected outpatients
with inflammatory rheumatic diseases [8]. For the
present study, cross-sectional data from the year 2013
from 16 arthritis centres were used.
The German biologics register (RABBIT—Rheumatoide
Arthritis Beobachtung der Biologika Therapie) is an
ongoing prospective, observational cohort study on the
long-term safety and effectiveness of biologic and syn-
thetic disease-modifying anti-rheumatic drug (DMARD)
treatment in RA patients. Patients are eligible for enrol-
ment at the start of treatment with a biologic or synthetic
DMARD after failure of at least one DMARD. The register
began in 2001 and contains patient data from approxi-
mately 350 rheumatologists nationwide. The patients are
observed for up to 10 years [9].
All data sources provide information on demographics,
details on rheumatologic visits, including laboratory tests,
joint counts, and additional health information. They
represent patients under routine rheumatologic care in a
population-based setting. Prior to enrolment, all patients
give their informed consent. All databases received ethical
approval by the Ethics Committee of the Charité
University Medicine, Berlin.
Data from the German microcensus and the German
Ageing Survey were available as reference data. We
found no differences between both data sources regard-
ing the distribution of BMI, stratified by age (in years)
and sex. Due to access to anonymized data on the indi-
vidual person level, we selected the German Ageing Sur-
vey (DEAS) which has been provided by the Research
Data Centre (FDZ-DEAS) of the German Centre of
Gerontology (DZA) [10]. The DEAS is a longitudinal
survey for the analysis of life situations and biographies
of people in the second half of their lives. The data are
based on nationally representative surveying (cross-sec-
tional and longitudinal) of some more than 6000 partici-
pants from the age of 40 years onwards.
Study design
We analysed the data from the inclusion visit in CAPEA
and RABBIT and cross-sectional data from the NDB from
the year 2013. The data were stratified by age, sex, and
disease duration, and were compared separately for each
RA cohort with data from the DEAS from the year 2008.
Outcome and covariate assessment
The primary outcome was the BMI, which was calcu-
lated as the weight in kilograms divided by height in me-
tres squared. It was classified into four groups according
to the definition of the World Health Organization
(WHO): underweight (<18.5 kg/m2, normal weight
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(18.5– < 25 kg/m2), overweight (25– < 30 kg/m2), and
obese (≥30 kg/m2) [2].
Socio-demographics and clinical data were collected
from the respective databases using the most recent (2013
for NDB) or baseline values (CAPEA, RABBIT). The fol-
lowing variables were investigated as covariates: age, sex,
disease duration, C-reactive protein (CRP; mg/l), disease
activity score of 28 joints (DAS28) and its components
(erythrocyte sedimentation rate (ESR; mm/h), tender joint
count (TJC), swollen joint count (SJC), and patient global
assessment (NRS 0–10)). In addition, rheumatoid factor
(RF), anti-citrullinated protein antibodies (CCP), func-
tional capacity by Hannover Functional Assessment Ques-
tionnaire (FFbH; range 0–100, 100 representing full
capacity) [11], smoking status (current/former/never),
level of education (high/moderate/low), the number of
comorbid conditions (reported by the rheumatologist), the
number of current DMARDS, and the current gluco-
corticoid dose (mg/day) were documented.
Statistical analysis
The baseline characteristics were compared between the
RA cohorts and the population controls. The prevalence
of obesity was compared by a sample proportion test.
The associations between BMI and socio-demographics
were investigated using non-parametric tests. Regarding
the association of BMI and markers of disease activity,
generalized linear models (with normal or negative-




Data relating to 1033 patients with early arthritis
(CAPEA), 12,230 patients with active RA after treatment
failure (RABBIT), and 3424 unselected patients treated
in rheumatology (NDB) were included in the present
analysis and compared with data relating to 6202 popu-
lation controls (DEAS). The patient characteristics are
presented in Table 1.
The mean age in the NDB was comparable to the
DEAS, whereas CAPEA and RABBIT patients were on
average 4 years younger. The proportion of females was
higher in the arthritis patients than in the controls. The
mean DAS28 values of the arthritis cohorts reflected the
varying disease activity at the onset (CAPEA), prior to a
switch to a biologic or other csDMARD therapy after
failure (RABBIT), and under current therapy (NDB).
Taking the controls as reference, the strongest differ-
ence regarding BMI categories was found for obese
patients, who were more frequently in all arthritis
cohorts (all P < 0.01). Regarding the proportion of
underweight patients, the difference was less promin-
ent. Despite different disease duration and disease
activity, all cohorts had a very similar BMI distribu-
tion (Fig. 1). The apparent differences to the normal
population persisted when the comparison was
additionally stratified by age decades.
Distribution of BMI by age and sex
According to the age and sex differences in the cohorts
and the reference group, the data were stratified, and
each cohort was compared separately against the refer-
ence group. Table 2 shows the BMI distribution by sex
and age groups in the arthritis cohorts and the reference
data. The higher prevalence of obesity was most promin-
ent in the age group <55 years. The prevalence of
obesity remained independent of the disease duration.
Association between BMI categories, demographics, and
disease activity
Patient characteristics and markers of disease activity
with regard to the BMI categories are presented in
Table 3. In all cohorts, overweight and obese patients
Table 1 Patient characteristics of the arthritis cohorts and controls
CAPEA RABBIT NDB Reference (DEAS)
N 1033 12,230 3424 6202
Age (years), mean (SD) 56.6 (14.2) 56.2 (9.7) 61.5 (13.7) 61.5 (12.1)
Sex (female), n (%) 660 (63.9) 9328 (76.3) 2611 (76.3) 3072 (49.5)
Disease duration (weeks or years), mean (SD) 12.6 w (7.2) 9.9 y (9.1) 13.5 y (10.6) NA
CRP (mg/l), mean (SD) 19.7 (30.3) 18.2 (26.6) 11.0 (5.2) NA
DAS28, mean (SD) 5.1 (1.3) 5.2 (1.3) 3.1 (1.2) NA
BMI (kg/m2), mean (SD) 27.0 (5.0) 26.7 (5.3) 26.5 (4.9) 26.6 (4.2)
< 18.5, n (%) 11 (1.1) 263 (2.2) 56 (1.6) 45 (0.8)
18.5 to <25, n (%) 372 (36.4) 4810 (39.3) 1416 (41.4) 2264 (37.5)
25 to <30, n (%) 396 (38.8) 4294 (35.1) 1219 (35.6) 2624 (43.5)
≥ 30, n (%) 243 (23.8) 2863 (23.4) 733 (21.4) 1099 (18.2)
BMI body mass index, CRP C-reactive protein, DAS28 Disease Activity Score, NA not applicable, SD standard deviation, w weeks, y years
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were on average 4 years older compared to patients
with normal weight. The age at the onset of RA
differed, being earlier in underweight patients in
RABBIT and NDB (−6.1 years RABBIT, P < 0.01;
−1.5 years NDB, P = 0.61) and later in overweight and
obese patients (+3 years CAPEA, P < 0.001; +4.3 years
RABBIT, P < 0.01; +3.4 years NDB, P < 0.001) com-
pared to normal-weight patients. This result was
confirmed with a separate analysis of 2264 patients
with a disease duration <6 months in the entire
National Database: these early RA patients (mean
disease duration 3.0 months) also showed a later dis-
ease onset in overweight/obese compared to normal-
weight status (+6 years, P < 0.001).
In all cohorts, a high educational level was strongly
under-represented in obese patients. Current smoking
was negatively and former smoking was positively asso-
ciated with the BMI. Only in RABBIT and CAPEA were
obese patients less often seropositive. In all cohorts, the
DAS28 and ESR were increased in obese patients,
whereas SJCs were not; CRP was only slightly increased
in CAPEA and the NDB. The doses of glucocorticoids
(average over last 6 months) were not associated with
the BMI in the NDB (P = 0.55) and RABBIT (P = 0.89).
Underweight patients presented with an overall high
disease activity in CAPEA and higher SJCs and labora-
tory markers in RABBIT. Compared to normal weight,
functional capacity measured by FFbH was lower in
Fig. 1 Body mass index distribution. The body mass index (BMI) was used to present the distribution of weight in the early arthritis cohort
(CAPEA) and in patients with prevalent RA in the National Database (NDB) and in the biologics register (RABBIT) compared to the general
population in the age group 40–79 years




40– < 55 55– < 70 ≥70 Total 40– < 55 55– < 70 ≥70 Total
CAPEA <18.5 1.0 1.0 2.9 1.4 0.9 0.8 0 0.6
18.5 to <25 40.4 34.2 33.1 36.3 35.7 24.8 32.0 30.6
25 to <30 32.7 34.6 42.5 35.8 43.8 52.0 45.0 47.2
≥30 26.0 30.2 21.6 26.5 19.6 22.4 23.0 21.7
RABBIT <18.5 2.6 1.7 2.0 2.1 0.5 0.7 0.5 0.6
18.5 to <25 43.2 37.2 38.2 39.6 30.0 27.2 33.9 29.3
25 to <30 29.8 35.3 36.8 33.6 45.5 46.7 49.9 46.8
≥30 24.4 25.8 23 24.8 24 25.3 15.8 23.3
NDB <18.5 2.0 1.2 2.4 1.8 1.0 0.3 0.7 0.6
18.5 to <25 48.9 40.6 40.8 42.8 35.4 25.4 34.8 31.3
25 to <30 26.0 34.3 36.5 33.0 43.9 49.8 48.4 47.8
≥30 23.1 23.9 20.3 22.4 19.7 24.4 16.0 20.2
DEAS <18.5 1.1 1.4 1.2 1.2 0.3 0.1 0.5 0.3
18.5 to <25 54.9 43.4 36.7 45.7 34.4 26.9 28.6 29.8
25 to <30 29.9 36.8 39.9 35.2 49.4 51.9 52.8 51.4
≥30 14.1 18.4 22.2 17.9 15.9 21.1 18.2 18.5
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Table 3 Clinical characteristics by BMI categories
CAPEA RABBIT NDB
BMI (kg/m2) <18.5 18.5 to <25 25 to <30 ≥30 <18.5 18.5 to <25 25 to <30 ≥30 <18.5 18.5 to <25 25 to <30 ≥30
Age (years), mean (SD) 58.8 (14.9) 54.2 (15.6) 58.2 (13.6) 57.8 (12.6) 49.8 (15.8) 54.3 (13.7) 58.1 (11.6) 57 (10.9) 59.9 (16.6) 59.7 (15.0) 63.4 (12.6) 61.5 (12.2)
Age at disease onset (years), mean 58.6 53.9 58.0 57.5 37.7 43.9 48.2 48.3 44,4 45,9 50,1 48,1
Disease duration (years), mean (SD) 0.2 0.3 0.2 0.3 12 (9.9) 10.4 (9.3) 9.9 (9.1) 8.8 (8.5) 15.5 (11.2) 13.8 (10.4) 13.3 (10.8) 13.4 (10.5)
Education, high (%) 40.0 21.4 16.4 13.3 22.4 21.7 14.3 11.8 28.3 27.9 18.6 15.7
Smoking, current (%) 63.6 36.3 32.3 27.6 30 24.2 20.7 18 35.7 22.4 19.8 13.8
Smoking, former (%) 9.1 23.9 28.0 39.1 12.9 20.9 25.4 28.7 16.7 25.1 30.9 36.3
RF positive (%) 45.5 55.4 49.8 46.9 73.3 74.7 71.6 66.4 72.2 72.4 69.9 72.3
DAS28, mean (SD) 5.9 (0.7) 4.9 (1.3) 5.1 (1.3) 5.2 (1.2) 5.2 (1.3) 5.1 (1.4) 5.2 (1.4) 5.3 (1.3) 3.0 (1.3) 3.0 (1.2) 3.1 (1.2) 3.4 (1.2)
SJC, mean (SD) 9.2 (5.8) 6.4 (5.5) 6.7 (5.7) 6.2 (5.1) 7.1 (5.5) 6.8 (5.6) 6.6 (5.6) 6.2 (5.5) 1.5 (2.4) 1.4 (2.6) 1.3 (2.7) 1.4 (3.1)
TJC, mean (SD) 10.5 (5.2) 9.7 (6.1) 10.4 (6.7) 10.7 (6.5) 8.7 (6.9) 8.7 (6.9) 9 (7) 9.4 (7.1) 1.7 (3.3) 2.0 (3.7) 1.9 (3.6) 2.3 (3.7)
PGA, mean (SD) 6.2 (2.3) 5.2 (2.3) 5.4 (2.3) 5.7 (2.1) 5.9 (2.2) 5.8 (2.1) 6 (2.1) 6.2 (2.1) 4.1 (2.7) 3.8 (2.2) 4.1 (2.2) 4.6 (2.2)
ESR, mean (mm/h) 42.8 (28.3) 31.5 (23.8) 31.9 (23.1) 35.7 (24.0) 32.6 (25.3) 30.2 (23.3) 31.5 (23.1) 32.2 (21.8) 18.2 (16.6) 18.0 (15.7) 19.1 (16.4) 23.1 (17.6)
CRP, mean (mg/l) 19.4 (34.3) 19.0 (34.5) 19.8 (26.5) 20.6 (29.2) 20.6 (29.9) 18.4 (27.9) 18.3 (26.1) 17.4 (24.8) 7.2 (9.8) 9.3 (65.2) 9.9 (50.8) 10.4 (17.9)
FFbH (0–100),
mean (SD)
69.9 (17.8) 78.9 (19.0) 74.2 (21.5) 71.2 (21.0) 62.5 (24.7) 66.6 (22.9) 62.9 (23.2) 58.4 (23.1) 74.8 (25.5) 77.2 (23.1) 72.6 (24.0) 67.9 (24.4)
No. of comorbidities, mean (SD) 0.4 (0.5) 0.6 (1.0) 1.0 (1.3) 1.5 (1.6) 1.2 (1.6) 1.2 (1.5) 1.6 (1.7) 2.0 (1.7) 2.7 (2.3) 2.3 (2.1) 2.7 (2.2) 2.8 (2.2)
Prednisone equivalent in mg/day, mean (SD)* NA NA NA NA 5.3 (4.8) 5.1 (5.5) 5.1 (5.5) 5.3 (7.8) 5.9 (4.0) 4.8 (3.4) 4.8 (3.0) 5.2 (3.8)
*Average daily dose in the last 6 months. In CAPEA, prior treatment with prednisone was not applicable (NA)
BMI body mass index, ESR erythrocyte sedimentation rate, DAS28 Disease Activity Score, FFbH Hannover Functional Assessment, PGA Patient Global Assessment, SJC swollen joint count, TJC tender joint count, RF














underweight and decreased with rising BMI in all
cohorts. In a separate analysis of males and females, sex-
specific differences in the relation between BMI and
ESR, and CRP and FFbH were observed (Additional files
1: Table S1, 2: Table S2 and 3: Table S3).
To further evaluate the observed differences regarding
the association between BMI and the single components
of the DAS28, linear models with separate analyses for
males and females were performed. Age, disease duration,
and glucocorticoid dose (only NDB and RABBIT) were
included for adjustment. In females, ESR values were
higher in underweight and in obese compared to normal-
weight patients in all cohorts. In contrast, in males, ESR
values were lower in underweight patients of CAPEA and
the NDB and in obese patients of RABBIT compared to
normal-weight status. In all cohorts, but especially in
RABBIT and in CAPEA, there was an increasing disparity
between TJCs and SJCs in higher BMI categories (Fig. 2).
Discussion
The analysis of three arthritis cohorts within the collab-
orative METARTHROS network enabled comparison of
the BMI distribution in RA patients and the general
population. Compared to the reference data, a higher
prevalence of obesity was observed in all RA cohorts.
Since the reference sample does not exclude persons
with RA and other inflammatory diseases, the differences
compared to healthy persons is rather underestimated.
The prevalence rate of approximately 24 % is higher than
that reported from former RA cohorts [12, 13], but similar
to current data from the UK [14, 15]. In contrast to the
general population, where obesity is equally frequent in
females and males, in all RA cohorts it was more frequent
in females. The predominance of obesity in female RA
patients has already been reported from the Rochester
cohort [4]. Reasons for this disparity remain unclear and
cannot be explained with the current data. Besides female
sex, former smoking and a lower educational level were
associated with higher BMI categories. Current smoking
was present in the majority of patients with a low BMI but
in the minority of obese patients. In addition, obese
patients were less frequently seropositive in two of the
present cohorts. In other cohorts, seronegative RA has
already been reported to be associated with a higher BMI
[6]. In accordance with the negative association with
smoking, both factors can lead to the reported link of
obesity and less structural damage [12, 16], independent
of the disease activity or functional status. Increased joint
pain and worse functional capacity in obese patients, both
of which are observed in the present study, can also result
from obesity and its referring comorbid conditions rather
than from RA severity [6].
RA manifested at a later age in overweight and obese
patients. This is supported by recent data from large
Fig. 2 Association between BMI categories and markers of disease activity. Results from generalized linear models for a ESR in females, b ESR in
males, c joint counts in females and d joint counts in males, adjusted for age, disease duration, glucocorticoid dose (except for CAPEA), and ESR
(in the joint count analysis). BMI body mass index, ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint count
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population-based Swedish health survey where a higher
BMI was associated with a reduced risk of future RA in
men, but not in women [17]. The higher proportion of
obese patients was already present in the early arthritis
cohort CAPEA, where the mean symptom duration of
arthritis was less than 4 months. It is possible that being
overweight or obese is an acquired risk factor that be-
comes apparent at an older age. We observed increased
joint pain and worse functional capacity in obese pa-
tients, which was debated by otherauthors to rather re-
sult from obesity itself and the referring comorbid
conditions than from RA severity [6].
The heterogeneous association of various covariates
with BMI categories shows that cause and impact of
obesity on RA outcomes can hardly be judged. Other as-
pects linked to obesity, such as physical activity, failed
attempts to lose weight, co-medication, and treatment
adherence, probably affect clinical RA outcomes.
Regarding the relation between BMI and markers of
disease activity, the composite score DAS28 is not an ap-
propriate measure as it masks the different associations
of the single components of the DAS28 as well as age-
and sex-specific differences in the markers of disease ac-
tivity [18]. In the present study, the effect of the BMI on
inflammatory markers was not very pronounced. How-
ever, joint counts do have a substantial influence on
DAS28 values and the dissociation between TJCs and
SJCs in obese patients may be responsible for underesti-
mating joint activity in obese patients. This distinct
behaviour should be recognized when analysing the
impact of BMI on treatment response.
Other interactions may be responsible for the effect
observed on the ESR in females. Hormones, cytokines,
growth factors, and intracellular regulators can modify
the course of inflammation [19], and may be differently
distributed in females.
Limitations and strengths
The BMI was used with WHO definitions for underweight,
overweight and obesity; however, it does not measure adi-
pose tissue. The body composition might be more precisely
represented by waist circumference, dual-energy X-ray ab-
sorptiometry, and fat mass indexes using bioelectrical im-
pedance [5, 20]. We selected the BMI as a surrogate for
obesity and underweight as it was obtained in all arthritis
cohorts and in the reference group. By using the BMI we
could compare a very large dataset at different stages of
the disease with the general population, and results could
be discussed against the background of data from other
cohorts using the same BMI categories [2, 4, 14].
Conclusions
An increased prevalence of obesity was found in all RA
cohorts. A delayed onset of RA was observed in
overweight and obese patients. Prospective data are
needed to analyse BMI development prior to and its in-
fluence on RA onset, since obesity could be approached
in prevention campaigns. Differences in the age at onset,
the clinical presentation, and the presence of rheumatoid
factor in normal-weight and obese patients may partly
explain the obesity paradox in the structural course of
RA. The predominance of obesity in females and the dif-
ferent behaviour of ESR values in relation to BMI in fe-
males necessitate further investigation when analysing
the impact of obesity on inflammation in RA.
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